BioSpace News Archive

The industry analysis report is considered a valuable source of information about the global Gonorrhea Testing industry and lays stress on the future market scope, emerging industry trends, industry statistics, and market growth potential during the forecast years.

Zosano Pharma Corporation, a clinical-stage biopharmaceutical company, provided a corporate update.

Hikma Pharmaceuticals PLC (Hikma) confirms that it has not entered into any transaction with Opiant Pharmaceuticals, contrary to a PR Newswire announcement issued today indicating that Opiant Pharmaceuticals and Hikma have entered into a commercialisation and license agreement for OPNT003, Nasal Nalmefene, in Europe and the UK.

The data has been collected through extensive primary and secondary research and is validated by experts in the industry.

Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases today announced that the company will be presenting preclinical data on its two lead candidates for geographic atrophy (GA) and wet AMD at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting.

Sutro Biopharma, Inc. announced that on April 26, 2022, the Compensation Committee of Sutro’s Board of Directors granted 155,000 of Sutro Biopharma stock options and 18,000 Restricted Stock Units of Sutro common stock to two new employees.

Eiger BioPharmaceuticals, Inc. reported that the Compensation Committee of Eiger’s Board of Directors granted stock options to purchase an aggregate of 290,000 shares of Eiger’s common stock to two newly hired employees.

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, in collaboration with the University of Oxford, today announced final results from its Phase 2b study in patients with Dupuytren’s disease.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2021.

The Muscular Dystrophy Association celebrates yesterday’s approval by the US Food and Drug Administration (FDA) to ravulizumab (Ultomiris) for the treatment of generalized myasthenia gravis (gMG) in adults who test positive for the anti-acetylcholine receptor (AChR) antibody.